Literature DB >> 7717835

Criteria for selection of a payment method for inpatient medical rehabilitation.

S Tepper1, G DeJong, D Wilkerson, R Brannon.   

Abstract

This article presents the results of a 3-stage Delphi survey designed to identify the policy criteria that should govern the evaluation of alternative payment methods and guide the selection of a payment method for inpatient medical rehabilitation. The Delphi survey (n = 85) included four groups of participants: consumers (n = 8), providers (n = 35), payers (n = 15), and health services researchers (n = 27). The Delphi survey uncovered 16 evaluation criteria. Delphi participants evaluated each criterion on a 10-point scale (1 = not important; 10 = greatest importance). Respondents value maximize patient/family outcome, maximize access, and maximize efficiency as the three most important criteria. Respondents report that minimize financial risk is the least important criterion. The results from both stage 2 and stage 3 (response rate = 85%) indicate a high level of consensus across the four respondent groups.

Entities:  

Mesh:

Year:  1995        PMID: 7717835     DOI: 10.1016/s0003-9993(95)80660-1

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  3 in total

1.  The relation of socioeconomic factors and racial/ethnic differences in US asthma mortality.

Authors:  E N Grant; C S Lyttle; K B Weiss
Journal:  Am J Public Health       Date:  2000-12       Impact factor: 9.308

2.  Length of stay and hospital readmission for persons with disabilities.

Authors:  K J Ottenbacher; P M Smith; S B Illig; R C Fiedler; C V Granger
Journal:  Am J Public Health       Date:  2000-12       Impact factor: 9.308

Review 3.  Complementarity of Clinician Judgment and Evidence Based Models in Medical Decision Making: Antecedents, Prospects, and Challenges.

Authors:  Zhou Lulin; Ethel Yiranbon; Henry Asante Antwi
Journal:  Biomed Res Int       Date:  2016-08-24       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.